During the last session, AlloVir Inc (NASDAQ:ALVR)’s traded shares were 0.61 million, with the beta value of the company hitting 0.74. At the end of the trading day, the stock’s price was $0.95, reflecting an intraday gain of 2.52% or $0.02. The 52-week high for the ALVR share is $2.48, that puts it down -161.05 from that peak though still a striking 38.95% gain since the share price plummeted to a 52-week low of $0.58. The company’s market capitalization is $108.11M, and the average intraday trading volume over the past 10 days was 0.27 million shares, and the average trade volume was 179.82K shares over the past three months.
AlloVir Inc (ALVR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 4.00. ALVR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.09.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AlloVir Inc (NASDAQ:ALVR) trade information
AlloVir Inc (ALVR) registered a 2.52% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.52% in intraday trading to $0.95, hitting a weekly high. The stock’s 5-day price performance is 18.73%, and it has moved by 16.51% in 30 days. Based on these gigs, the overall price performance for the year is -38.09%. The short interest in AlloVir Inc (NASDAQ:ALVR) is 4.89 million shares and it means that shorts have 26.44 day(s) to cover.
AlloVir Inc (ALVR) estimates and forecasts
Statistics show that AlloVir Inc has outperformed its competitors in share price, compared to the industry in which it operates. AlloVir Inc (ALVR) shares have gone up 19.47% during the last six months, with a year-to-date growth rate more than the industry average at 77.05% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 76.90% this quarter and then jump 66.70% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -70.96%. While earnings are projected to return 72.86% in 2024, the next five years will return 29.50% per annum.
ALVR Dividends
AlloVir Inc is due to release its next quarterly earnings on 2024-Nov-01. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AlloVir Inc (NASDAQ:ALVR)’s Major holders
AlloVir Inc insiders own 49.21% of total outstanding shares while institutional holders control 42.98%, with the float percentage being 84.62%. ECOR1 CAPITAL, LLC is the largest shareholder of the company, while 90.0 institutions own stock in it. As of 2024-06-30, the company held over 11.29 million shares (or 9.8479% of all shares), a total value of $8.17 million in shares.
The next largest institutional holding, with 9.8 million shares, is of OCTAGON CAPITAL ADVISORS LP’s that is approximately 8.5447% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $7.09 million.
